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Abstract
Background: Undercarboxylated osteocalcin (ucOC) increases insulin sensitivity in mice. In humans, data are supportive, but
the studies are mostly cross-sectional. Exercise increases whole-body insulin sensitivity, in part via ucOC, while acute glucocorticoid
treatment suppresses ucOC in humans and mice.
Objectives: A single dose of prednisolone reduces the rise in ucOC produced by exercise, which partly accounts for the failed
increase in insulin sensitivity following exercise.
Methods: Healthy young men (n=12) aged 18 to 40 years will be recruited. Initial assessments will include analysis of fasting
blood, body composition, aerobic power (VO2peak), and peak heart rate. Participants will then be randomly allocated, double-blind,
to a single dose of 20 mg of prednisolone or placebo. The two experimental trials will involve 30 minutes of interval exercise
(90%-95% peak heart rate), followed by 3 hours of recovery and 2 hours of euglycaemic- hyperinsulinaemic clamp (insulin
clamp). Seven muscle biopsies and blood samples will be obtained at rest, following exercise and post-insulin clamps.
Results: The study is funded by the National Heart Foundation of Australia and Victoria University. Enrollment has already
commenced and data collection will be completed in 2016.
Conclusion: If the hypothesis is confirmed, the study will provide novel insights into the potential role of ucOC in insulin
sensitivity in human subjects and will elucidate pathways involved in exercise-induced insulin sensitivity.
(JMIR Res Protoc 2016;5(2):e78)   doi:10.2196/resprot.5119
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Introduction
Insulin resistance is characterized by impaired insulin action in
target tissues. Skeletal muscle is a major site of glucose uptake
and disposal in response to insulin and skeletal muscle can
become insulin resistant in obese individuals and those with
type 2 diabetes mellitus (T2DM). In mice, the skeleton is partly
involved in determining insulin secretion, insulin sensitivity,
and glucose tolerance via the undercarboxylated form of
osteocalcin (ucOC) [1,2]. UcOC- deficient mice have insulin
resistance and in obese mice recombinant ucOC treatment
reduces glucose levels and increases insulin secretion and
sensitivity [2,3]. Moreover, recombinant ucOC increases muscle
glucose uptake post ex vivo contraction in mice [4].
In humans, ucOC may influence glycemic control but most
evidence is based on cross-sectional studies [5,6]. For example,
patients with T2DM have lower serum ucOC than controls. A
lower serum ucOC is associated with a higher fasting glucose
and fat mass, and lower insulin sensitivity [7,8]. This suggests
ucOC participates in glucose homeostasis in humans; however,
prospective interventional studies are required [9].
Exercise increases insulin sensitivity in nonobese and obese
subjects and in patients with T2DM independent of weight loss
[10] Even a single bout of exercise increases glucose handling
and insulin sensitivity [11]. Acute exercise also increases ucOC,
which is associated with improved glycemic control and
increased insulin sensitivity post exercise [7,12,13]. Thus, ucOC
may contribute to the regulation of insulin sensitivity in humans.
To explore this, we have designed a prospective study aimed
at inhibiting the rise in ucOC using a single dose of a
glucocorticoid (GC). GC treatment is used regularly as an
anti-inflammatory and immunosuppressive agent [14,15].
Long-term GC treatment causes bone loss, obesity, insulin
resistance, and T2DM[16]. The detrimental long-term effects
of GC on insulin resistance are partly mediated via osteoblasts,
the bone cells responsible for the production of ucOC [14,15,17].
The reduction in insulin sensitivity following short-term GC
treatment is related to an acute reduction in osteoblastic function
and ucOC levels and not to the GC effects on skeletal muscle
or liver, at least in mice [17]. As such, we will use a single dose
of a GC, prednisolone, as a tool to acutely suppress ucOC and
examine the consequent effect on whole-body insulin sensitivity
and muscle metabolism, including measuring GC signaling in
muscle. The regulation of GC-target genes,
glucocorticoid-induced leucine zipper (Gilz)[18] and
FK506-binding protein 5 (Fkbp5)[19] will be analyzed by
polymerase chain reaction (PCR) and Western blot from muscle
biopsies of humans with and without an acute dose of
prednisolone. We hypothesize that the protein levels of these
GC-targets will not be altered in the short time frame, even if
gene expression is altered. Other studies in mice and humans
confirm a 40% to 50% reduction in circulating OC within 12
to 24 hours after the commencement of GC treatment [20]. On
the other hand, 5 days of prednisone treatment had minimal
effect on muscle protein synthesis, breakdown, mitochondrial
function, strength, and resting energy expenditure in men [21].
Thus, evidence from mice and humans indicates that a reduction
in serum OC and ucOC following GC treatment occurs prior to
muscle atrophy signaling changes in skeletal muscle. We
hypothesize that insulin sensitivity will be partly reduced due
to changes in insulin signaling proteins subsequent to a reduction
in circulating ucOC levels.
No previous research has used GC (prednisolone) as a tool to
examine the effect of ucOC on insulin sensitivity post exercise.
Thus, the aim of this study is to test the hypothesis that
attenuation of the increase in ucOC following exercise by a
single dose of prednisolone reduces insulin sensitivity post
exercise, as measured by euglycaemic-hyperinsulinaemic clamp,
as well as impairing skeletal muscle insulin signaling. We also
hypothesize that markers of muscle damage will not be increased
by a single dose of prednisolone.
Methods
Study Design and Participants
This is designed as a double-blind, randomized controlled,
cross-over study. We aim to recruit 12 healthy young men.
Volunteers will be recruited via several advertisement strategies
including flyers, global emails to staff and students from Victoria
University, and Web-based advertisements.
Criteria
Healthy young men aged 18 to 40 years, body mass index range
between 19 and 27 kg/m2with fasting blood glucose ≤ 5.6
mmol/L1will be recruited for the study. Men with bone disease
(such as osteoporosis), metabolic or cardiovascular disease,
and/or those who are taking any medication known to affect
bone metabolism, insulin secretion, or insulin sensitivity will
be excluded. Also, those with a musculoskeletal and/or
orthopedic condition (such as severe osteoarthritis) that prevents
normal daily function (such as walking) will be excluded.
Conversion of ucOC to OC is dependent on vitamin K [22]. As
such, volunteers on warfarin therapy or vitamin K
supplementation or restriction will be excluded.
Sample Size and Data Analysis
The sample size is based on our previous work where exercise
significantly increased ucOC by approximately 6.5% and insulin
sensitivity by approximately 35% during a
euglycaemic-hyperinsulinaemic clamp (n=11) [7,12]. As such,
we estimate that the sample size needed in this cross-over design
(power of 80%, alpha=0.05) is 12 individuals.
Descriptive statistics will be used to describe the volunteers’
characteristics as well as the study measurements. Changes from
pre-to-post exercise within each trial and between trials will be
analyzed by paired t-tests. General linear model analysis of the
variance will be use to compare multiple time-points within and
between interventions. Multilinear regression model will be
used to determine associations between selected measurements.
All data will be reported as mean ± standard error of mean and
all statistical analyses will be conducted at the 95% level of
significance ( P≤.05).
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Screening
Fasting blood test: a blood sample will be collected following
an overnight fast. Blood will be analyzed at Austin Health
pathology using the standard hospital assay protocols for
glucose, HbA1c, insulin, triglyceride, low-density lipoprotein,
and high-density lipoprotein.
Body composition: dual-energy x-ray absorptiometry (DXA)
will be used to assess total body fat and lean body mass. In
addition, the DXA will be used to assess fat mass in the
abdominal region as well as bone mineral density to exclude
osteoporosis [23,24].
Aerobic power (VO2peak) will be assessed during a sign and
symptom-limited graded exercise test as we previously described
[23]. The exercise will be performed on a cycle ergometer and
VO2for each 15-second interval will be measured by a gas
analyzer that will be calibrated as per the manufacturer’s
instructions before each test. Participants will be asked to refrain
from physical activity (48 hours), and alcohol and caffeine
ingestion (24 hours) prior to the screening session and trial days.
Randomization and Blinding
At the conclusion of the baseline/screening assessments
volunteers will be randomly allocated (block allocation) in a
double-blind fashion to determine the order of the treatments
(prednisolone or placebo). Randomization will be performed
using sealed opaque envelopes. The person responsible for the
randomization, the investigators and the participants will not
be aware of the intervention (prednisolone or placebo). The
code for the randomization will be held by the medical
practitioner who will supervise the insulin clamp to allow
medical intervention in case of adverse responses during the
exercise or insulin clamps.
Intervention
Volunteers will attend our laboratory twice for the experimental
trials (Figure 1). On the day prior to the first trial, participants
will be asked to record their daily diet in a food diary, which
will then be replicated the day prior to their second trial. The
two trials (prednisolone or placebo) will be performed 1 to 3
weeks apart. This ensures that the effect of the single dose of
prednisolone is “washed out” [25]. Twenty-four hours prior to
the first trial day, and a minimum of 1 week after the VO2peaktest,
a single muscle biopsy and 15 ml of blood will be obtained. To
avoid an additional biopsy, data from this resting biopsy will
be used as the “24 hour prior” time-point for both the placebo
and prednisolone trials. Then, at 7 PM (12 hours before the trial)
on the day prior to each experimental trial participants will
ingest a 20-mg capsule of prednisolone or placebo orally
(Avicel- microcrystalline Cellulose NF PH105) (Figure 1).
The timing of the prednisolone ingestion is based on previously
published data on the suppressive effect of acute GC treatment
on osteocalcin [20]. The prednisolone dose that will be used in
this study is slightly higher compared with the dose used by
Nielsen et al [20] (10 mg), but is lower compared with doses
used in clinical practice to treat inflammatory conditions (30-70
mg/day). Both the prednisolone and placebo will be purchased
from the same pharmacy and look and taste identical. Avicel is
widely used as a placebo in a variety of drug trials [26].
The following day (the trial day) participants will attend our
laboratory in the morning (7 AM) after an overnight fast for the
experimental trial (Figure 1). The participant will lie down on
a bed and a cannula will be inserted to the antecubital vein. Then
a resting blood sample will be obtained. In addition, a resting
muscle biopsy will be obtained from the vastus lateralis, under
local anesthesia (Xylocaine 1%), using the percutaneous needle
biopsy technique as previously described [12]. Exercise will
commence 10 to 20 minutes after the resting muscle biopsy.
The high intensity exercise will be performed as previously
described and will consist of a 6-minute warm-up at 50% to
60% of peak heart rate followed by 4 × 4-minute intervals at
90% to 95% peak heart rate (HRpeak) and a 2-minute warm-down
at 50% to 60% of peak heart. The high-intensity intervals will
be separated by 2 minutes of active recovery consisting of
cycling at 50% to 70% of peak intensity [12]. Peak heart rate
will be defined as the highest heart rate measured during the
incremental test.
After completing the exercise, participants will recover for 3
hours and blood samples will be taken immediately, 30 minutes,
1, 2, and 3 hours post exercise (Figure 1). Then, a 2-hour
euglycaemic-hyperinsulinaemic clamp (insulin clamp) will be
performed. During the clamp blood samples (∼1-1.5 ml) will
be taken every 5 minutes to monitor blood glucose levels. A
10-ml blood sample will be taken every 30 minutes during the
clamp (see Figure 1) for the analysis of OC, ucOC, insulin, and
other markers of bone formation and resorption (the hormones
CTX and procollagen 1 N-terminal propeptide (P1NP)). Blood
will be centrifuged (10 min at 3500 rpm, 4°C) and serum and
plasma will be immediately stored in aliquots at −80ºc until
assayed. In addition, a total of three muscle biopsies from the
vastus lateralis will be undertaken in each experimental session.
Muscle will be analyzed for insulin signaling proteins, markers
of muscle inflammation and atrophy signaling proteins. In total,
seven muscle biopsies will be obtained during the study. Four
biopsies will be obtained during the first session (−24, baseline
and pre and post insulin clamp) and three during the second
session (baseline and pre and post insulin clamp).
A euglycemic-hyperinsulinemic clamp (insulin clamp) will be
performed as previously reported [12,27,28]. Prior to the insulin
clamp a single slow release tablet of potassium chloride (600
mg) will be given to reduce the risk of potassium depletion
during the insulin clamp. Venous blood samples, from a heated
arm vein, will be collected prior and during each session. Insulin
will be infused at 40 mU.m-2per minute for 120 minutes
generating an elevated, stable insulin concentration in the last
30 minutes of the clamp. Insulin sensitivity will be assessed by
the glucose infusion rate (GIR, mg·kg-1·min-1) during the last
30 minutes of the insulin-stimulated period and the GIR per
unit of insulin (M-Value) [29]. During both
euglycemic-hyperinsulinemic clamp sessions, exogenous
glucose will be variably infused to achieve the target blood
glucose of approximately 5 mmol/L for the duration of the
clamp.
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Figure 1. Experimental design. Participants will perform the protocol twice. Prednisolone (GC), or placebo (Pla) orally in a double-blind, randomized,
cross-over design. The two experimental days will be separated by 1 to 3 weeks. The -24 hour biopsy will be obtained only once, prior to the first
treatment. We will use the data from this biopsy for comparison across the 2 trial days.
Analysis
Total serum OC will be measured using an automated
immunoassay. Serum ucOC will be measured by the same
immunoassay after adsorption of carboxylated OC on 5 mg/mL
hydroxyl-apatite slurry, following the method described by
Gundberg et al [30]. β-isomerized C-terminal telopeptides (a
bone resorption marker) and P1NP (a bone formation marker)
will be analyzed at Austin pathology.
Muscle insulin signaling proteins, markers of muscle
inflammation and atrophy signaling proteins (see below for
details) will be measured by PCR and immunoblotting.
Glucocorticoid signaling in muscle will be also monitored by
quantitative reverse-transcription PCR analysis of
glucocorticoid-target genes, Gilzand Fkbp5. Protein expression
of the GILZ and Fkbp5 will also be analyzed by
immunoblotting. Muscle mitochondrial respiration will be
measured using Oxygraph O2k, to assess the effects of
prednisolone and exercise on mitochondrial function.
Safety Consideration
This is an invasive study that includes seven muscle biopsies
(in total), two insulin clamps, blood sampling, high intensity
exercise, and administration of a single dose of prednisolone.
To reduce the risk associated with the study, only healthy young
individuals will participate. In addition, only those who meet
the inclusion criteria (as described above) will participate.
During the initial graded exercise test participants will be
monitored via a 12-lead electrocardiogram (ECG) to identify
cardiac abnormalities that may exclude them from the study. A
12-lead ECG will also be used during the insulin clamps.
Participants will be asked to report side effects associated with
the administration of prednisolone (and placebo). In case of an
adverse response/event the participant will be seen by the
medical practitioner involved in the study. All the participants
will receive a copy of their results (blood tests, body
composition, and aerobic fitness).
Ethical Considerations
This study was approved by Victoria University Human
Research Ethics Committee (Application ID: HRE14-099). The
trial has been registered in the Australian New Zealand Clinical
Trials Registry [ANZCTR, ID ACTRN12610000943044]. The
investigator, regardless of the outcome, will publish the results
of the study.
Outcomes Measurements
Primary outcomes are changes in serum ucOC and changes in
insulin sensitivity (glucose infusion rate per unit of insulin).
Secondary outcomes are measures of skeletal muscle insulin
signaling proteins for total and phosphorylated forms of protein
kinase B, Akt substrate of 160 kDa, and Insulin receptor
substrate 1 and 2, mitochondria function and markers of muscle
inflammation including interleukin-6, tumor necrosis
factor-alpha, monocyte chemotactic protein 1, interleukin 1
beta, atrogin, signal transducer and activator of transcription 3,
nuclear factor kappa-light-chain-enhancer of activated B cells,
forkhead box protein O1, and Muscle RING-finger protein-1.
In addition, glucocorticoid-target genes, gilzand Fkbp5will be
measured. G protein-coupled receptor class C group 6 member
A will also be measured as it is the likely receptor for ucOC in
skeletal muscle. In blood, changes in bone remodeling markers
include total osteocalcin, P1NP, and beta-isomerized C-terminal
telopeptides.
Discussion
Principal Findings
In mice, ucOC is a modulator of insulin sensitivity and ucOC
treatment reduces the risk for type 2 diabetes [2,3]. In humans,
data are supportive but are based on cross-sectional studies. If
this study shows that suppression of ucOC with a single dose
of prednisolone leads to suppression of insulin sensitivity post
exercise, this suggests that ucOC is likely to participate in the
modulation of insulin sensitivity in humans.
Insulin resistance is characterized by impaired insulin action in
insulin target tissues. However, muscle glucose uptake is normal
during and following exercise in patients with type 2 diabetes
[31,32]. As such, understanding the mechanism/s behind the
insulin sensitizing effect of exercise on muscle and whole-body
glucose uptake can open the door for new therapeutic treatments
for T2DM. In this study we focus on ucOC as acute exercise
increases ucOC and higher ucOC correlate with an improvement
in insulin sensitivity and glycemic control after exercise in obese
men [7,12,13].
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A single dose (10 mg) of prednisone suppresses OC and ucOC,
an effect that lasts for at least 12 hours [20]. We hypothesize
that prednisolone will attenuate the increase in ucOC in response
to exercise and that this will coincide with reduced insulin
sensitivity compared with placebo. This design will enable us
to examine whether changes in ucOC levels are related to
changes in insulin sensitivity in young healthy men. We also
aim to determine the fraction of the observed reduction in insulin
sensitivity that is modulated by ucOC in humans.
A potential limitation of the current study is that GC are known
to effect several other organs/tissues and not only osteoblasts.
As such, it is plausible that a reduction in insulin sensitivity
following acute GC treatment may not be entirely due to the
reduction in ucOC. However, in mice the reduction in ucOC
and insulin sensitivity occurred prior to the GC-induced effects
in muscle, liver, and adipose following short-term GC treatment
suggesting that the changes in insulin sensitivity are related to
the reduction in ucOC levels and not to the GC effects on
skeletal muscle, fat, or liver [17]. Nevertheless, in the current
study we will be able to identify if acute GC treatment has
immediate effects on GC-target genes ( gilz, Fkbp5, fatty acid
binding protein 4, hydroxysteroid (11-Beta) dehydrogenase 1,
peroxisome proliferator-activated receptor gamma, and
CCAAT/enhancer-binding protein alpha), and any detrimental
effect on skeletal muscle, as markers of muscle atrophy and
degradation will also be measured.
Another limitation is that the current study will investigate
young, healthy men rather than patients with T2DM. As such,
it will not be possible to generalize the results to this population.
Follow-up studies will be required to confirm that changes in
ucOC following interventions are related to changes in insulin
sensitivity in patients with T2DM.
Conclusions
Current evidence connecting ucOC to insulin sensitivity in
humans is supportive, but driven by cross-sectional studies. The
current dynamic study will add important knowledge concerning
the role of ucOC in insulin sensitivity in humans post exercise.
The project is relevant to understanding pathway/s involved in
exercise-induced insulin sensitivity and the potential for using
osteoblast altering drugs as a target to improve insulin sensitivity
in diseases like diabetes and obesity.
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DXA: dual-energy x-ray absorptiometry
ECG: electrocardiogram
Fkbp5: FK506-binding protein 5
GC: glucocorticoid
Gilz: glucocorticoid-induced leucine zipper
GIR: glucose infusion rate
P1NP: procollagen 1 N-terminal propeptide
PCR: polymerase chain reaction
T2DM: type 2 diabetes mellitus
ucOC: undercarboxylated osteocalcin
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